Alphina Therapeutics Strengthens Management Team with Appointment of Marc Damelin, Ph.D. as Chief Scientific Officer [Yahoo! Finance]
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $5.00 price target on the stock.
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024